Patient Support

A guide to how the IRA is reshaping Medicare Part D, price negotiations, manufacturer liability, and pharmacy operations, along with what it means for access, adherence, and commercial strategy.

Rare disease drugs now drive innovation, investment, and portfolio strategy as policy incentives, scientific advances, and market success reshape biopharmaceutical growth.

In today’s Pharma Pulse, UK regulators seize thousands of fake weight loss pens, while new data reveals that the "miracle jab" is financially out of reach for nearly 70% of users.

From new formulations and vial formats to retailer expansion and pricing pressure, evolving GLP-1 strategies are transforming distribution models, reimbursement dynamics, and long-term supply planning.

In the final part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, argues that while Medicare price controls may reduce federal spending, they have yet to meaningfully improve patient access—contending that true reform must address insurance design, out-of-pocket costs, and the long-term impact on life sciences innovation and investment.

The company is significantly lowering the US list prices for its popular weight loss and diabetes GLP-1 drugs, signaling a broader shift in pricing strategy as competition intensifies and access pressures grow.

In today’s Pharma Pulse, Eli Lilly launches the monthly Zepbound KwikPen to streamline obesity care, while Gilead Sciences moves to acquires Arcellx in a massive expansion of its cell therapy portfolio.

While the Inflation Reduction Act introduces a $2,100 out-of-pocket cap and payment smoothing options for Medicare Part D beneficiaries, low awareness and persistent health literacy gaps threaten to limit their real-world impact—highlighting the need for coordinated action across providers, pharmacies, industry, and advocacy groups.

The GLP-1 landscape continues to evolve in both delivery formats and affordability.

The retailer is now accepting NovoCare savings programs for Wegovy and Ozempic, offering introductory discounts and adding access to oral Wegovy.

Community pharmacies are being squeezed out of local markets, creating pharmacy deserts that raise costs, reduce access, and strain the healthcare system.

These hubs can streamline access, reduce friction across reimbursement and logistics, and improve outcomes, as the CGT pipeline expands and patient demand accelerates.

A four-pillar strategy to help ensure both, as copay programs face mounting payer pressure and misuse in 2026.

Policy shifts bring meaningful improvements for some—but looming coverage losses and rising premiums threaten to erase those gains.

By unifying data, workflows, and decision-making across partners, AI orchestration is enabling healthcare supply chains to move from reactive firefighting to proactive resilience—supporting faster responses, smarter tradeoffs, and more reliable patient care delivery.

In today’s Pharma Pulse, a new national survey exposes the depth of America’s prescription access crisis, while AstraZeneca and Eli Lilly commit billions of dollars to next-generation weight-loss therapies and domestic manufacturing.

In this Q&A, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, discusses rising insurance costs, widening affordability gaps, and growing pressure on the healthcare safety net.

This guide breaks down how AFPs function and why they are fundamentally changing the path between patients and their therapies.

In today’s Pharma Pulse, the AAP defies federal vaccine cuts, Morris & Dickson scales its specialty footprint, and Insilico Medicine targets cardiometabolic health with a new partnership.

In today’s Pharma Pulse, extreme weather tests the resilience of community pharmacies, while CMS proposes a near-flat 0.09% update for Medicare Advantage and Part D payments in 2027.

In today’s Pharma Pulse, global pharmaceutical production hits a surge as manufacturers brace for US tariff shifts, while a new study reveals how smart speakers are slashing A1C levels for older adults.

How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.

In the second part of his Pharma Commerce video interview, Hari Kiran Chereddi, CEO of HRV Pharma, describes how AI-driven orchestration, real-time data integration, and federated learning are reshaping pharmaceutical supply chains for faster, safer, and more agile operations.

In the final part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, explains how understanding premiums, coverage trade-offs, and HSAs remains a major challenge for patients—and for policymakers designing new plans.

In the fourth part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, outlines the financial pressures that make sustained safety net protections a healthcare imperative.